Regorafenib vs placebo for Refractory Advanced Gastric Cancer, summarised by Erman Akkus

Erman Akkus shared a post on X:

“Regorafenib vs placebo for Refractory Advanced Gastric Cancer
INTEGRATE Journal of Clinical Oncology

At least 2 lines of previous therapy for advanced disease
Median OS: 4.5 vs 4 mo
HR: 0.70 (0.56 to 0.87) P = .001

12-month survival rates: 19% vs 6%
mPFS: 1.8 vs 1.6 mo
 HR: 0.53 [0.40 to 0.70] P < .0001
delayed deterioration in global QoL

Although statistically significant, clincially not significant benefit Use in 1st and 2nd line?

Phase 2 First-line regorafenib with nivolumab and chemotherapy >can be safely combined
Phase III trials planned.”

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

Authors: Nick Pavlakis, et al.

Source: Erman Akkus/X

Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.